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Background. Histoplasma capsulatum is the most common endemic mycosis in the United States and is a frequent cause of
opportunistic infection in immunodeficient hosts. Histoplasmosis is most often self-limiting and goes unrecognized in the
immunocompetent population but can progress to disseminated histoplasmosis in patients with an impaired immune system. Liver
involvement as a part of disseminated histoplasmosis which usually originates in the lung is well known. However, extrapulmonary
hepatic histoplasmosis as a primary manifestation is extremely rare. Case Presentation. We report a rare case of histoplasmosis
that presented as persistent fever and abnormal liver function tests in a 66-year-old female with rheumatoid arthritis, receiving
infliximab. Conclusion. Emphasizing histoplasmosis as a major cause of acute granulomatous hepatitis and fever of unknown origin
in cell mediated immunodeficient population, this case highlights the need for high index of suspicion and the importance of prompt
diagnosis since any delay of treatment can be life threatening in this population.

1. Background

2. Case Presentation

Histoplasma capsulatum var. capsulatum is the most common
cause of endemic mycosis in the US. It remains a frequent
cause of opportunistic infection in patients with compromised immune status, iatrogenic or related to human immunodeficiency virus (HIV). The vast majority of histoplasmosis
is subclinical. It either goes unrecognized or presents as a
mild influenza like illness, and the small proportion who
develop progressive disseminated histoplasmosis are the
immunosuppressed population [1]. Liver involvement as a
part of disseminated histoplasmosis is well known. However,
liver infection as primary manifestation of histoplasmosis,
without evidence of primary lung involvement is rare. Here
we report a case of histoplasmosis presenting with acute
granulomatous hepatitis.

The patient is a 66-year-old Caucasian female who presented to our hospital with three weeks history of fever of
unknown origin with no specific pattern, associated with
nausea, vomiting, fatigue, and pruritus. The patient was
already admitted twice to an outside hospital within the last
month and underwent extensive diagnostic workup. She had
a bronchoscopy with BAL studies as well as lung biopsy of
an incidental 1.6 cm right lower lobe lung nodule, seen on
imaging studies, with no definite diagnosis.
Her past medical history is significant for 16 years history
of rheumatoid arthritis, for which she has been on methotrexate for the last 8 years and infliximab for the last 6 years.
At the outside hospital, she was found to have elevated liver
enzymes with subsequent discontinuation of methotrexate
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and infliximab. The patient was started on prednisone at a
dose of 40 mg daily.
Upon arrival to our hospital, the patient was found to
have a fever of 103∘ F with chills and tachycardia, along with
painless jaundice, fatigue, nausea, and vomiting.
She denies any history of sick contacts, unpasteurized
milk, or undercooked meat intake. Upon further questioning,
she reports that her fever started only two days after a
long road trip with her husband, from Michigan to Florida.
On their way, and 11 days prior to her symptoms started,
they stopped at Pittsburg, Kansas, where they stayed for 6
days. The patient endorsed horseback riding in Pittsburg but,
however, denied any sick contacts.
Her examination was notable for an awake, alert, and
oriented patient with icteric sclerae. Her respiratory rate was
18 breaths per minute and was saturating 98% on room air.
There was no hepatosplenomegaly or abdominal tenderness
and the rest of the examination was normal.
Laboratory examination revealed hemoglobin of
12.3 g/dL, white cell count of 7.9 with 40% granulocytes, 43%
lymphocytes and 7% monocytes, and platelets of 230. Liver
function tests revealed alanine aminotransferase 252 IU/L
(0–60 IU/L), aspartate aminotransferase 173 IU/L (0–
46 IU/L), alkaline phosphatase of 375 IU/L (44–147 IU/L),
total bilirubin 4.2 mg/dL (0-1 mg/dL), corrected calcium
8.7 mg/dL (8.5–10.5 mg/dL), PT 11.4 (9–12.5 sec), total protein
of 7 mg/dL, and an albumin of 2.5 mg/dL. Autoimmune
markers, including serum antimitochondrial antibodies,
were negative, except for RF and anti-CCP. Blood cultures
and urine culture remained negative.
Ultrasound of the abdomen was normal. The chest Xray again revealed a right lower lobe pulmonary nodule.
Computed tomography (CT) of the chest showed a 1.3 cm
right lower lobe pulmonary nodule which corresponds to the
abnormality seen on chest X-ray. CT of the abdomen showed
normal appearance and size of liver, pancreas, spleen, and
adrenals.
Outside records were reviewed and bronchial washings
had grown only Candida albicans on routine bacterial and
fungal cultures. Cytology was consistent with mixed inflammatory cells with no evidence of microorganism on Grocott’s
methenamine silver (GMS) stain. Right lower lobe nodule
CT guided needle biopsy was only consistent with focal
acute and chronic inflammation, along with scattered yeast
elements consistent with candida species, with no evidence
of granulomas or tumor.
CMV PCR and hepatitis serologies were negative. EBV
blood PCR came back positive with 1959 copies/cc (IgG VCA
positive, IgM VCA negative). Serum RPR and QuantiFERON
test for tuberculosis were negative. Serum cryptococcal antigen from outside hospital was negative.
Empiric antibiotics consisting of vancomycin and piperacillin-tazobactam were discontinued after final blood cultures reported no growth and patient remained febrile.
Transthoracic echocardiogram was compatible with grade 1
diastolic dysfunction, normal ejection fraction, and no vegetation. An ultrasound guided liver biopsy, done on hospital
day two, was consistent with granulomatous hepatitis with
negative acid fast stain, and subsequently steroids were
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Figure 1: Liver tissue with Grocott’s methenamine silver stains
(GMS) showing round to ovoid 2–4 micrometers narrow based
budding fungal organisms.

restarted. Cryptococcal antigen and Brucella, Bartonella and
Q fever serologies were all negative. Liver biopsy immunohistochemical stain with in situ hybridization studies was also
negative for EBV. On hospital day five, after additional stains
on liver specimen were performed, pathological examination
reported that fungal organism was identified within areas of
granulomatous inflammation, largely within histiocytes on
hematoxylin and eosin staining. They were further described
as round to ovoid 2–4 micrometers narrow based budding
fungal organisms on GMS staining suggestive of histoplasmosis (Figure 1). Three days later, serum histoplasma
antigen, by quantitative MVista Histoplasma antigen enzyme
immunoassay (EIA) detection test, reported strongly positive
with titers above the limit of quantification, above 19 ng/mL.
Meanwhile, patient clinical condition deteriorated and
progressed into a respiratory failure with bilateral interstitial
infiltrates on chest imaging requiring mechanical ventilation.
Intravenous liposomal amphotericin B at a dose of 3 mg/kg q
24 hrs was ultimately started. Fungal culture from bronchoalveolar lavage eventually grew Histoplasma capsulatum.
The patient became afebrile on day five of amphotericin and
her jaundice started to resolve. Her chest X-ray cleared and
was extubated. The patient was switched on day seven to
itraconazole secondary to acute kidney injury. Antifungal
therapy was subsequently switched to voriconazole once she
developed a bleeding peptic ulcer disease requiring intravenous proton pomp inhibitor while being on itraconazole.
Patient’s liver function tests completely normalized in six
weeks.

3. Discussion
Granulomatous hepatitis is an important cause of fever of
unknown origin in up to 13% of patients [2]. Granulomatous
hepatitis may be the first clue to an ongoing systemic
disease. This entity has a broad differential that goes from
autoimmune disorders like sarcoidosis and primary biliary
cirrhosis to malignancy, drugs, and systemic infections like
tuberculosis, fungal infections, Q fever, and brucellosis or it
may be idiopathic [3]. Clinically these patients are usually
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symptomatic with elevated liver function tests and fever of
unknown origin [4].
Histoplasmosis is a thermal dimorphic fungus found
most commonly in soil along the Ohio and Mississippi
River Valleys, in the central, mid-Atlantic, and south-central
states, and from Alabama to southwest Texas. When soil is
disturbed by excavation or construction, the spores become
airborne and are inhaled [1]. In highly prevalent areas,
such as Indianapolis and Kansas City, more than 80% of
the population has been exposed to histoplasma through
inhalation of airborne spores. Once in the alveoli they
convert to a yeast form, which is the tissue invasive form.
The current multiplying yeasts are phagocytosed by alveolar
macrophages that are initially incapable of killing the fungus.
The ingested yeasts multiply inside the macrophages and are
spread throughout the body via the lymphatics during the
preimmune phase of the illness to organs rich in reticuloendothelial cells [5]. Hematogenous dissemination usually
occurs during the first 2 weeks before cellular immunity
develops [6]. In an immunocompetent host, once adequate
cell-mediated immunity develops, the infection is eliminated
by cytokines including interleukin-12 and interferon gamma
that help “armed” macrophages in either killing the organism
or halt its progression by forming a calcified granuloma [7].
In immunosuppressed individuals, especially with defective
cell mediated immunity, like our patient, these defense
mechanisms are impaired leading to reactivation of old foci
or a progressive dissemination involving the extrapulmonary
tissues [8]. The typical incubation time is 7–21 days [1].
A variety of well-known conditions can predispose to
disseminated histoplasmosis, that is, AIDS, immunosuppressive medications such as glucocorticoids, antirejection therapies in solid organ transplantation or TNF alpha inhibitors
therapies, primary immunodeficiency, and extremes of age
[9–11]. Histoplasma capsulatum is a well-recognized but
uncommon cause of granulomatous hepatitis. Liver often is
involved in the course of progressive disseminated disease
usually originating in the lungs. Patients with primarily liver
involvement present with nonspecific symptoms like fever of
unknown origin, nausea, vomiting, fatigue, weight loss, and
elevation of liver function tests as seen in our patient and
previously reported cases [12, 13].
A diagnosis of disseminated histoplasmosis can be made
using various methods like antigen detection, cultures, serology, or direct microscopy. The gold standard is the recovery
of the organism from biologic extrapulmonary material [5].
In our case, the granuloma on the histopathologic exam and
the microscopic demonstration of histoplasma provided a
rapid and definitive proof of dissemination. Fungal culture
of the tissue samples can provide a definitive diagnosis as
well, but it will take at least 1 month to ensure isolation,
with a 80% sensitivity only if multiple specimens are submitted [14]. However, as a quick and reliable assay, tests for
serum and urine histoplasma polysaccharide antigen remain
the mainstay of diagnosis. Based on multicenter evaluation
of MVista Histoplasma antigen EIA of 218 patients with
histoplasmosis, antigenuria was detected in 92% of PDH
(progressive disseminated histoplasmosis) cases, including
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95% of those with AIDS, 93% of those with other immunocompromising conditions, and 73% of patients not known
to be immunocompromised. Among patients with PDH for
whom serum and urine samples were tested, antigenuria was
detected in 97% and antigenemia in 100% [15]. Because 2 to
6 weeks may be required for the appearance of antibodies,
serology is less useful for patients who have severe acute
infection and in immunocompromised patients, who mount
a poor response [11]. Serology sensitivity is only 70% in the
immunocompromised population and particularly only 20%
for patients taking TNF alpha inhibitors [16]. Imaging studies
lack sensitivity and specificity and have very limited role in
the diagnosis of granulomatous hepatitis.
Prompt diagnosis and initiation of antifungal therapy are
crucial in patients with impaired cell mediated immunity
with fatality rate of 100% if left untreated [1]. The two agents
most commonly used for the treatment of histoplasmosis
include amphotericin B and itraconazole. For moderately
severe to severe disease, liposomal amphotericin B (3 mg/kg
daily) is recommended for 1-2 weeks, followed by oral
itraconazole (200 mg 3 times daily for 3 days and then 200 mg
twice daily for a total of at least 12 months) [17]. Itraconazole
can be used initially in patients with mild-to-moderate disease. Lifelong suppressive therapy with itraconazole (200 mg
daily) may be required in immunosuppressed patients if
immunosuppression cannot be reversed [17]. Fluconazole is
not as active as itraconazole against Histoplasma capsulatum.
Voriconazole and Posaconazole have good in vitro activity
against histoplasma but are not commonly used. Resistance
can emerge during voriconazole therapy but has not been
described with Posaconazole [18]. Antigen levels in urine can
be used to monitor a patient response to treatment, even
though most of these reported studies were done with AIDS
patients [11]. Antigen levels decline by the end of 12 weeks;
most of the decline was seen in the first 2 weeks of therapy,
more rapidly in serum than in urine [19]. An increase in
antigen concentration raises concern for relapse or treatment
failure and further evaluation of the adequacy of treatment is
indicated [11].
Our patient had 6-year history of cell mediated immunodeficiency as a well-known risk factor for disseminated
histoplasmosis; this long interval makes this presentation
more consistent with a recent exposure and spore inhalation
while horseback riding in an endemic area rather than
a reactivation of prior infection. The pathogenesis behind
early liver involvement and lung sparing in the initial presentation remains unexplained. This finding has been well
reported with tuberculosis after infliximab therapy, where the
majority of patients had extrapulmonary tuberculosis (56%)
[20]. Moreover, there is always the possibility of subclinical
primary lung involvement that was underdiagnosed in this
patient. In the latter case, the ability of the patient to mount
a well formed granulomatous reaction selectively in the liver
and failure of granuloma formation in the lung remains unexplained. In addition, her clinical deterioration after stopping
TNF blockers raises the possibility of immune reconstitution
inflammatory syndrome (IRIS) [16]. High clinical suspicion
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is critical for early diagnosis because if was left untreated;
the infection can disseminate further over the next 2 to 12
weeks leading to a high fatality rate [21].

4. Conclusion
Disseminated histoplasmosis presenting as granulomatous
liver disease is rare. High index of suspicion is warranted in
patients with impaired cell mediated immunity, who present
with fever of unknown origin and elevated liver function
tests, especially if the patient has resided or visited an endemic
area. Rapid diagnosis by antigen testing or by histopathologic
examination is essential to facilitate institution of appropriate
antifungal therapy and minimize mortality.
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